<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T05:15:31Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27903" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27903</identifier><datestamp>2026-09-24T04:29:05Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Xie, Feng</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Kennedy, Kevin Mackenzie</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Research Methodology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-10-04T13:44:01Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-10-04T13:44:01Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27903</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/14836</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Cost-utility is a method that integrates clinical factors of disease progression with cost and&#xd;
consequence to patient’s overall health state. Cost-utility analyses describe the trade-offs that&#xd;
are consequences of interventions and are commonly used to support health policy decision&#xd;
making. Well constructed cost-utility analyses can improve access patients have to effective&#xd;
interventions and move past ineffective or exceedingly costly interventions. The methods&#xd;
employed to assess incremental effectiveness of glaucoma interventions have advanced over&#xd;
time, where investigators have adapted to standards for reporting and modeling strategies.&#xd;
However, most cost-utility analyses use a restrictive set of utility values from foundational,&#xd;
but outdated work. Glaucoma cost-utility analyses combine utility values from patient&#xd;
preferences, on multiple scales of measurement. These methodological flaws in the use&#xd;
and reporting of utility values limit the internal validity of the study and external validity in&#xd;
generalizing the results to broader populations. Common generic preference-based measures&#xd;
of health utility, including the EuroQol 5 Dimension 3/5 Level (EQ-5D-3/5L), lack the&#xd;
sensitivity to detect health state changes in patients with glaucoma.&#xd;
The three main investigations of this dissertation aimed to describe the current methodological issues in glaucoma cost-utility investigations, validate a condition-specific preferencebased measure (HUG-5) in a sample of patients with various stages of glaucoma, and&#xd;
generate a preference-based weighting algorithm for glaucoma health states for US general&#xd;
population. A systematic review of cost-utility analyses in the literature revealed that most&#xd;
all cost-utility analyses failed to document rationale for including health utility estimates or&#xd;
conduct a review of appropriate utilities for relevant health states. Most authors of cost-utility&#xd;
analyses did not recognize or describe the limitations of combining utilities from multiple&#xd;
scales of measurement and from different preference sources. In a psychometric validation&#xd;
of the HUG-5, a sample of patients with glaucoma completed the NEI-VFQ-25, the HUG-5,&#xd;
and the EQ-5D-5L to describe their quality of life and health state. The HUG-5 dimensions&#xd;
described similar dimensions measured by National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) scales and differentiated from unrelated dimensions with adequate&#xd;
test-retest reliability on 3 month follow up. To model utility values to HUG-5 health states,&#xd;
a multi-attribute disutility function (MADUF) was estimated from the preferences of the&#xd;
US general population. A preference-weighting algorithm assigned utility values to the&#xd;
3125 health states measured by the HUG-5. In validating the MADUF with directly elicited&#xd;
marker health states, the MADUF performed similar in mean absolute error relative to other&#xd;
related studies for the Health Utilities Index Mark 3 (HUI-3) and Patient-Oriented Prostate&#xd;
Utility Scale (PORPUS).&#xd;
This work has significant implications for investigators evaluating glaucoma interventions&#xd;
with cost-utility comparisons, providing an alternative measure of utility on the policy scale&#xd;
with a condition-specific preference-based measure.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Cost-utility is a method used to support decision making for which treatments are available&#xd;
and how much they should cost. Utility is a value that reflects the severity of a health state&#xd;
and the preferences of a population for that health state. Patients with glaucoma lose their&#xd;
vision over time, resulting in worse health states and eventually blindness. It is difficult&#xd;
to measure the additional value of treatments in glaucoma because the usual measures&#xd;
of health state do not capture changes in health experienced by patients with glaucoma.&#xd;
Previous cost-utility studies use a variety of sources to estimate the utility of preferences.&#xd;
The objective of this dissertation was to describe the use and application of a preferencebased glaucoma-specific measure of utility (HUG-5), validate the measure with glaucoma&#xd;
patients, and develop an algorithm that assigns preference weights to the measure. This work&#xd;
identifies common issues in cost-utility studies of glaucoma interventions, describes the&#xd;
properties of the HUG-5 in a sample of glaucoma patients and reports a preference-weighted&#xd;
algorithm for converting HUG-5 health states to utilities that describe the preferences of the&#xd;
US general population.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Glaucoma</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Health Utility</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Multi-attribute disutility</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Psychometric validation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Systematic Review</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cost utility analysis</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Measuring and valuing glaucoma health states</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>